Patents by Inventor DEODIAL GUY GUIADEEN

DEODIAL GUY GUIADEEN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 2-AMINO-N-HETEROARYL-NICOTINAMIDES AS NAV1.8 INHIBITORS
    Publication number: 20250084064
    Abstract: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are inhibitors of Nav1.8 channel activity and may be useful in the treatment, prevention, management, amelioration, control and suppression of diseases mediated by Nav1.8 channel activity. The compounds of the present invention may be useful in the treatment, prevention or management of pain disorders, cough disorders, acute itch disorders, and chronic itch disorders.
    Type: Application
    Filed: November 26, 2024
    Publication date: March 13, 2025
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Ashok Arasappan, Ian M. Bell, Michael J. Breslin, Christopher James Bungard, Christopher S. Burgey, Harry R. Chobanian, Jason M. Cox, Anthony T. Ginnetti, Deodial Guy Guiadeen, Kristen L.G. Jones, Mark E. Layton, Hong Liu, Jian Liu, James J. Perkins, Shawn J. Stachel, Linda M. Suen-Lai, Zhe Wu
  • 2-amino-N-heteroaryl-nicotinamides as Na1.8 inhibitors
    Patent number: 12195445
    Abstract: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are inhibitors of Nav1.8 channel activity and may be useful in the treatment, prevention, management, amelioration, control and suppression of diseases mediated by Nav1.8 channel activity. The compounds of the present invention may be useful in the treatment, prevention or management of pain disorders, cough disorders, acute itch disorders, and chronic itch disorders.
    Type: Grant
    Filed: May 24, 2022
    Date of Patent: January 14, 2025
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Ashok Arasappan, Ian M. Bell, Michael J. Breslin, Christopher James Bungard, Christopher S. Burgey, Harry R. Chobanian, Jason M. Cox, Anthony T. Ginnetti, Deodial Guy Guiadeen, Kristen L. G. Jones, Mark E. Layton, Hong Liu, Jian Liu, James J. Perkins, Shawn J. Stachel, Linda M. Suen-Lai, Zhe Wu
  • BICYCLOHEPTANE PYRROLIDINE OREXIN RECEPTOR AGONISTS
    Publication number: 20230365533
    Abstract: The present invention is directed to bicyclo[4.1 0]heptane pyrrolidine compounds of formula (I) which are agonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.
    Type: Application
    Filed: August 16, 2021
    Publication date: November 16, 2023
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Stephane L. Bogen, Dane James Clausen, Deodial Guy Guiadeen, Jinsong Hao, Shishi Lin, Michael T. Rudd, Lan Wei, Li Xiao, Dexi Yang
  • 2-OXO-OXAZOLIDINE-5-CARBOXAMIDES AS NAV1.8 INHIBITORS
    Publication number: 20230227441
    Abstract: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are inhibitors of Nav1.8 channel activity and may be useful in the treatment, prevention, management, amelioration, control and suppression of diseases mediated by Nav1.8 channel activity. The compounds of the present invention may be useful in the treatment, prevention or management of pain disorders, cough disorders, acute itch disorders, and chronic itch disorders.
    Type: Application
    Filed: June 14, 2021
    Publication date: July 20, 2023
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Ashok Arasappan, Ian M. Bell, Christopher James Bungard, Christopher S. Burgey, Jason Michael Cox, Deodial Guy Guiadeen, III, Michael J. Kelly, III, Mark E. Layton, Hong Liu, Jian Liu, James T. Olsen, James J. Perkins, Jeffrey W. Schubert, Akshay A. Shah, Shawn J. Stachel, Michael David VanHeyst, Zhe Wu
  • Bicycloheptane pyrrolidine orexin receptor agonists
    Patent number: 11680060
    Abstract: The present invention is directed to bicyclo[4.1.0]heptane pyrrolidine compounds which are agonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.
    Type: Grant
    Filed: August 16, 2021
    Date of Patent: June 20, 2023
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Stephane L. Bogen, Dane James Clausen, Deodial Guy Guiadeen, Jinsong Hao, Shishi Lin, Michael T. Rudd, Lan Wei, Li Xiao, Dexi Yang
  • 2-AMINO-N-HETEROARYL-NICOTINAMIDES AS NAV1.8 INHIBITORS
    Publication number: 20220289710
    Abstract: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are inhibitors of Nav1.8 channel activity and may be useful in the treatment, prevention, management, amelioration, control and suppression of diseases mediated by Nav1.8 channel activity. The compounds of the present invention may be useful in the treatment, prevention or management of pain disorders, cough disorders, acute itch disorders, and chronic itch disorders.
    Type: Application
    Filed: May 24, 2022
    Publication date: September 15, 2022
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Ashok Arasappan, Ian M. Bell, Michael J. Breslin, Christopher James Bungard, Christopher S. Burgey, Harry R. Chobanian, Jason M. Cox, Anthony T. Ginnetti, Deodial Guy Guiadeen, Kristen L.G. Jones, Mark E. Layton, Hong Liu, Jian Liu, James J. Perkins, Shawn J. Stachel, Linda M. Suen-Lai, Zhe Wu
  • 2-amino-n-heteroaryl-nicotinamides as Na1.8 inhibitors
    Patent number: 11377438
    Abstract: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are inhibitors of Nav1.8 channel activity and may be useful in the treatment, prevention, management, amelioration, control and suppression of diseases mediated by Nav1.8 channel activity. The compounds of the present invention may be useful in the treatment, prevention or management of pain disorders, cough disorders, acute itch disorders, and chronic itch disorders.
    Type: Grant
    Filed: October 31, 2019
    Date of Patent: July 5, 2022
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Ashok Arasappan, Ian M. Bell, Michael J. Breslin, Christopher James Bungard, Christopher S. Burgey, Harry R. Chobanian, Jason M. Cox, Anthony T. Ginnetti, Deodial Guy Guiadeen, Kristen L. G. Jones, Mark E. Layton, Hong Liu, Jian Liu, James J. Perkins, Shawn J. Stachel, Linda M. Suen-Lai, Zhe Wu
  • BICYCLOHEPTANE PYRROLIDINE OREXIN RECEPTOR AGONISTS
    Publication number: 20220056017
    Abstract: The present invention is directed to bicyclo[4.1.0]heptane pyrrolidine compounds which are agonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.
    Type: Application
    Filed: August 16, 2021
    Publication date: February 24, 2022
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Stephane L. BOGEN, Dane James CLAUSEN, Deodial Guy GUIADEEN, Jinsong HAO, Shishi LIN, Michael T. RUDD, Lan WEI, Li XIAO, Dexi YANG
  • 2-AMINO-N-HETEROARYL-NICOTINAMIDES AS NAV1.8 INHIBITORS
    Publication number: 20210387966
    Abstract: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are inhibitors of Nav1.8 channel activity and may be useful in the treatment, prevention, management, amelioration, control and suppression of diseases mediated by Nav1.8 channel activity. The compounds of the present invention may be useful in the treatment, prevention or management of pain disorders, cough disorders, acute itch disorders, and chronic itch disorders.
    Type: Application
    Filed: October 31, 2019
    Publication date: December 16, 2021
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Ashok Arasappan, Ian M. Bell, Michael J. Breslin, Christopher James Bungard, Christopher S. Burgey, Harry R. Chobanian, Jason M. Cox, Anthony T. Ginnetti, Deodial Guy Guiadeen, Kristen L. G. Jones, Mark E. Layton, Hong Liu, Jian Liu, James J. Perkins, Shawn J. Stachel, Linda M. Suen-Lai, Zhe Wu
  • 5-alkyl pyrrolidine orexin receptor agonists
    Patent number: 11098029
    Abstract: The present invention is directed to 5-alkyl pyrrolidine compounds which are agonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.
    Type: Grant
    Filed: February 11, 2020
    Date of Patent: August 24, 2021
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Stephane L. Bogen, Dane James Clausen, Deodial Guy Guiadeen, Michael T. Rudd, Dexi Yang
  • 5-ALKYL PYRROLIDINE OREXIN RECEPTOR AGONISTS
    Publication number: 20200255403
    Abstract: The present invention is directed to 5-alkyl pyrrolidine compounds which are agonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.
    Type: Application
    Filed: February 11, 2020
    Publication date: August 13, 2020
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Stephane L. BOGEN, Dane James CLAUSEN, Deodial Guy GUIADEEN, Michael T. RUDD, Dexi YANG
  • 2-AMINO-N-HETEROARYL-NICOTINAMIDES AS NAV1.8 INHIBITORS
    Publication number: 20200140411
    Abstract: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are inhibitors of Nav1.8 channel activity and may be useful in the treatment, prevention, management, amelioration, control and suppression of diseases mediated by Nav1.8 channel activity. The compounds of the present invention may be useful in the treatment, prevention or management of pain disorders, cough disorders, acute itch disorders, and chronic itch disorders.
    Type: Application
    Filed: October 31, 2019
    Publication date: May 7, 2020
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Ashok Arasappan, Ian M. Bell, Michael J. Breslin, Christopher James Bungard, Christopher S. Burgey, Harry R. Chobanian, Jason M. Cox, Anthony T. Ginnetti, Deodial Guy Guiadeen, Kristen L. G. Jones, Mark E. Layton, Hong Liu, Jian Liu, James J. Perkins, Shawn J. Stachel, Linda M. Suen-Lai, Zhe Wu
  • SUBSTITUTED BICYCLIC HETEROARYL ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS
    Publication number: 20190308945
    Abstract: The present disclosure relates to compounds of formula (I) that are useful as modulators of ?7 nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly disorders of the central nervous system such as cognitive impairments in Alzheimer's disease, Parkinson's disease, and schizophrenia, as well as for L-DOPA induced-dyskinesia and inflammation.
    Type: Application
    Filed: October 30, 2017
    Publication date: October 10, 2019
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: BRENDAN M. CROWLEY, IAN M. BELL, ANDREW JOHN HARVEY, WILLIAM D. SHIPE, KENNETH J. LEAVITT, JOHN M. SANDERS, DEODIAL GUY GUIADEEN, LINDA M. SUEN, THOMAS J. GRESHOCK, VANESSA L. RADA
  • Btk inhibitors
    Patent number: 10214546
    Abstract: The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula (I), or pharmaceutically acceptable salts thereof, or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds of Formula (I) in the treatment of Btk mediated disorders.
    Type: Grant
    Filed: December 17, 2015
    Date of Patent: February 26, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Jian Liu, Joseph A. Kozlowski, Sobhana Babu Boga, Xiaolei Gao, Deodial Guy Guiadeen, Jiaqiang Cai, Shilan Liu, Dahai Wang, Hao Wu, Chundao Yang
  • Tertiary alcohol imidazopyrazine BTK inhibitors
    Patent number: 10208047
    Abstract: The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula I, or pharmaceutically acceptable salts thereof, Formula I or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds of Formula I in the treatment of Btk mediated disorders.
    Type: Grant
    Filed: December 17, 2015
    Date of Patent: February 19, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Jian Liu, Joseph A. Kozlowski, Brian M. Andresen, Sobhana Babu Boga, Xiaolei Gao, Deodial Guy Guiadeen, Jiaqiang Cai, Shilan Liu, Dahai Wang, Hao Wu, Chundao Yang
  • BTK inhibitors
    Patent number: 10130630
    Abstract: The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula (I), or pharmaceutically acceptable salts or stereoisomers thereof, or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds of Formula (I) in the treatment of Btk mediated disorders.
    Type: Grant
    Filed: December 17, 2015
    Date of Patent: November 20, 2018
    Assignee: MERCK SHARP & DOHME CORP.
    Inventors: Jian Liu, Joseph A. Kozlowski, Abdul-Basit Alhassan, Rajan Anand, Sobhana Babu Boga, Deodial Guy Guiadeen, Wensheng Yu, Younong Yu, Shilan Liu, Hao Wu, Chundao Yang
  • Benzamide imidazopyrazine Btk inhibitors
    Patent number: 10087188
    Abstract: The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula (I), or pharmaceutically acceptable salts thereof, or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds of Formula (I) in the treatment of Btk mediated disorders.
    Type: Grant
    Filed: December 17, 2015
    Date of Patent: October 2, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Jian Liu, Joseph A. Kozlowski, Abdul-Basit Alhassan, Sobhana Babu Boga, Xiaolei Gao, Deodial Guy Guiadeen, Jyhshing Wang, Wensheng Yu, Jiaqiang Cai, Shilan Liu, Dahai Wang, Hao Wu, Chundao Yang
  • Substituted imidazo[1,5-a]pyrazines as Btk inhibitors
    Patent number: 10040805
    Abstract: The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula (I), or pharmaceutically acceptable salts thereof, Formula (I) or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds of Formula I in the treatment of Btk mediated disorders.
    Type: Grant
    Filed: December 17, 2015
    Date of Patent: August 7, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Jian Liu, Joseph A. Kozlowski, Xiaolei Gao, Deodial Guy Guiadeen, Shilan Liu, Dahai Wang
  • BTK INHIBITORS
    Publication number: 20180118766
    Abstract: The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula (I), or pharmaceutically acceptable salts thereof, or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds of Formula (I) in the treatment of Btk mediated disorders.
    Type: Application
    Filed: December 17, 2015
    Publication date: May 3, 2018
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: JIAN LIU, JOSEPH A. KOZLOWSKI, SOBHANA BABU BOGA, XIAOLEI GAO, DEODIAL GUY GUIADEEN, JIAQIANG CAI, SHILAN LIU, DAHAI WANG, HAO WU, CHUNDAO YANG
  • BTK INHIBITORS
    Publication number: 20180079752
    Abstract: The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula (I), or pharmaceutically acceptable salts thereof, or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds of Formula I in the treatment of Btk mediated disorders.
    Type: Application
    Filed: May 31, 2016
    Publication date: March 22, 2018
    Applicants: MERCK SHARP & DOHME CORP., MERCK SHARP & DOHME B.V.
    Inventors: ADRIANUS PETRUS ANTONIUS DE MAN, RONALD KIM, JIAN LIU, JOSEPH A. KOZLOWSKI, SOBHANA BABU BOGA, THIERRY FISCHMANN, DEODIAL Guy GUIADEEN, ILSE HENDRICA MARIA POLS-DE ROOIJ, SHILAN LIU, HAO WU